贞芪六君抑癌汤配合培美曲塞联合奈达铂方案化疗对ⅢB～ⅣA期肺腺癌的影响  

Effect of Zhenqiliujunyiai Decoction Combined with Pemetrexed and Nedaplatin on Patients with Lung Adenocarcinoma of Stages ⅢB～ⅣA

作　　者：杨忠明 杨叶青 曾瑞 王杰 梅琳[2] 彭磊[2] 宋瑞蓉 刘丽 杨露银 Yang Zhongming;Yang Yeqing;Zeng Rui;Wang Jie;Mei Lin;Pen Lei;Song Ruirong;Liu Li;Yang Luyin(Department of Oncology,Traditional Chinese Medicine Hospital Affiliated to Southwest Medical University,Luzhou 646000,China;Department of Oncology,Pengzhou Hospital of Traditional Chinese Medicine,Pengzhou 611930,China)

机构地区：[1]西南医科大学附属中医医院肿瘤科,泸州646000 [2]四川省彭州市中医医院肿瘤科,彭州611930

出　　处：《成都医学院学报》2018年第6期677-680,658,共5页Journal of Chengdu Medical College

基　　金：国家卫生和计划生育委员会基金项目(No:W2015PM081)

摘　　要：目的探讨复方中药贞芪六君抑癌汤配合培美曲塞联合奈达铂(PN方案)对ⅢB～ⅣA期肺腺癌的疗效影响。方法回顾性分析2012年1月至2017年12月在西南医科大学附属中医医院和四川省彭州市中医医院ⅢB～ⅣA期肺腺癌住院患者共78例,采用数字随机法分为试验组(n=40)和对照组(n=38),两组均采用培美曲塞联合奈达铂化疗,培美曲塞500mg/m2第1天静滴,奈达铂80mg/m2第1天静滴;试验组采用复方中药贞芪六君抑癌汤配合治疗,化疗前1d开始服用,1剂/d,连服2周。结果试验组客观缓解率(objective response rate,ORR)为57.50%,对照组为39.47%(P>0.05);试验组疾病控制率(disease control rate,DCR)为80.00%,对照组为55.26%(P<0.05);试验组Ⅲ～Ⅳ°胃肠道反应、骨髓反应和肝功能损害与对照组比较明显减少(P<0.05);体力状况(karnofsky performance status,KPS)评分试验组优于对照组(P<0.05);试验组免疫功能监测CD3、CD4、CD4/CD8较治疗前升高(P<0.05);对照组免疫功能监测CD3、CD4、CD4/CD8较治疗前下降(P<0.05)。结论贞芪六君抑癌汤不能提高培美曲塞联合奈达铂治疗ⅢB～ⅣA期肺腺癌ORR,但是可以提高DCR,减轻骨髓抑制、胃肠道反应、体力状况下降和调控免疫等化疗所致的不良反应。Objective To evaluate the curative effect of Zhenqiliujunyiai Decoction combined with pemetrexed and nedaplation(PN regimen)on patients with lung adenocarcinoma of stagesⅢB~ⅣA.Methods The data of78cases with lung adenocarcinoma treated in Traditional Chinese Medicine Hospital Affiliated to Southwest Medical University and Pengzhou Hospital of Traditional Chinese Medicine from January of2012to December of2017were analyzed retrospectively.Those cases were randomly divided into the experiment group(n=40)and control group(n=38).The two groups were treated with the PN regimen and given the intravenous drip of500mg/m^2pemetrexed and80mg/m^2nedaplation at the first day.The experiment group was treated with Zhenqiliujunyiai Decoction additionally one day before thermotherapy and given one dose each for2weeks.Results The Objective response rates(ORR)in the experiment group and control group were57.50%and39.47%respectively,and the differences were statistically significant(P>0.05).The disease control rates(DCR)in the experiment group and control group were80.00%and55.26%respectively with statistical significance(P>0.05).The incidences of gastrointestinal reaction ofⅢ~Ⅳdegrees,bone marrow suppression and hepatic function damage in the experiment group were significantly less than those in the control group(P>0.05).The score of karnofsky performance status(KPS)were significantly higher in the experiment group than in the control group(P>0.05).The levels of CD3,CD4and CD4/CD8were significantly higher after treatment than before treatment in the experiment group(P>0.05),while those were significantly lower after treatment in the control group(P>0.05).Conclusion Zhenqiliujunyiai Decoction cannot improve ORR in the treatment of lung adenocarcinoma of stageⅢB~ⅣA with pemetrexed and nedaplation,but it can improve DCR,protect the immune regulation,and reduce the incidences of the adverse reactions including bone marrow suppression,gastrointestinal reaction ofⅢ~Ⅳdegrees and decline of physical strength.

关 键 词：肺腺癌 培美曲塞 奈达铂 复方中药 化疗反应 

分 类 号：R734.2[医药卫生—肿瘤]